National Research Corporation
NASDAQ•NRC
CEO: Mr. Michael D. Hays
セクター: Healthcare
業種: Medical - Healthcare Information Services
上場日: 2013-05-23
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.
連絡先情報
時価総額
$290.69M
PER (TTM)
24.1
53.6
配当利回り
4.1%
52週高値
$22.79
52週安値
$9.76
52週レンジ
順位24Top 10.8%
5.7
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 5.7 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$35.19M+0.00%
直近4四半期の推移
EPS
$0.08+0.00%
直近4四半期の推移
フリーCF
$6.06M+0.00%
直近4四半期の推移
2025 Q3 決算ハイライト
主なハイライト
Total Recurring Contract Value TRCV reached $141.66M as of September 30, 2025, showing growth of 7.6% over prior year period end.
Quarterly Revenue Decline Revenue for the quarter totaled $34.61M, a decrease of 3% compared to 2024, driven by existing client base softness.
Net Income Significantly Lower Net income for the three months ended was $4.12M, reflecting a substantial 27.5% decrease versus the prior year period.
New CFO Appointment Confirmed Shane Harrison appointed Executive Vice President and CFO effective September 29, 2025, bringing strong finance background.
リスク要因
Operating Cash Flow Decreased Cash provided by operating activities for nine months fell to $19.27M, down 32% from $28.25M in 2024.
SG&A Expenses Increased Selling, general, and administrative expenses rose 11.7% to $12.27M, driven by new CEO/executive compensation arrangements.
Higher Interest Expense Noted Total other expense increased due to higher interest expense of $0.8M from increased borrowings on Delayed Draw Term Loan.
Contingent Consideration Liability Contingent consideration liability remeasured at fair value, currently $474K, using Level 3 unobservable inputs impacting earnings.
見通し
Capital Allocation Priorities Set Board prioritizes funding innovation, growth investments, M&A activity, followed by quarterly dividends and share repurchases.
Debt Maturity Management Delayed Draw Term Loan principal amortization schedule detailed; maturity date set for February 6, 2030, with $27.6M availability.
Evaluating New Accounting Rules Company currently evaluating ASU 2025-06 regarding internal-use software capitalization; impact not yet reasonably estimable.
Stock Repurchase Program Status $20M repurchase authorization approved in April 2025; $9.3M spent repurchasing 618,264 shares through September 30, 2025.
同業比較
売上高 (TTM)
$349.88M
HCAT$316.06M
$254.79M
粗利益率 (最新四半期)
84.9%
78.3%
77.7%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| PBYI | $342.66M | 9.3 | 36.1% | 20.2% |
| SOPH | $322.27M | -4.3 | -93.9% | 38.8% |
| VMD | $316.49M | 23.2 | 10.1% | 12.2% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
1.6%
緩やかな成長
4四半期純利益CAGR
-32.3%
収益性の低下
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい
深度リサーチ
次回決算:2026年4月27日
EPS:-
|売上高:-
財務レポート
財務データ
全年度
Form 10-Q - Q3 2025
会計期末: 2025年9月30日|提出日: 2025年11月7日|売上高: $34.61M-3.4%|EPS: $0.18-25.0%不明Form 10-Q - Q2 2025
会計期末: 2025年6月30日|提出日: 2025年8月8日|売上高: $34.04M-2.8%|EPS: $-0.00-101.8%不明Form 10-Q - Q1 2025
会計期末: 2025年3月31日|提出日: 2025年5月9日|売上高: $33.55M-5.0%|EPS: $0.25-7.4%不明Form 10-K - FY 2024
会計期末: 2024年12月31日|提出日: 2025年3月17日|売上高: $143.06M-3.7%|EPS: $1.05-16.7%不明Form 10-Q - Q3 2024
会計期末: 2024年9月30日|提出日: 2024年11月8日|売上高: $35.82M-5.6%|EPS: $0.24-25.0%不明Form 10-Q - Q2 2024
会計期末: 2024年6月30日|提出日: 2024年8月8日|売上高: $35.02M-3.2%|EPS: $0.26-13.3%不明Form 10-Q - Q1 2024
会計期末: 2024年3月31日|提出日: 2024年5月9日|売上高: $35.31M-3.2%|EPS: $0.27-3.6%予想を下回るForm 10-K - FY 2023
会計期末: 2023年12月31日|提出日: 2024年2月27日|売上高: $148.58M-2.0%|EPS: $1.26-1.6%予想を上回る